» Articles » PMID: 36300088

Prognostic Significance and Identification of Basement Membrane-associated LncRNA in Bladder Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Oct 27
PMID 36300088
Authors
Affiliations
Soon will be listed here.
Abstract

Based on the importance of basement membrane (BM) in cancer invasion and metastasis, we constructed a BM-associated lncRNA risk model to group bladder cancer (BCa) patients. Transcriptional and clinical data of BCa patients were downloaded from The Cancer Genome Atlas (TCGA), and the expressed genes of BM-related proteins were obtained from the BM-BASE database. We download the GSE133624 chip data from the GEO database as an external validation dataset. We screened for statistically different BM genes between tumors and adjacent normal tissues. Co-expression analysis of lncRNAs and differentially expressed BM genes was performed to identify BM-related lncRNAs. Then, differentially expressed BM-related lncRNAs (DEBMlncRNAs) between tumor and normal tissues were identified. Univariate/multivariate Cox regression analysis was performed to select lncRNAs for risk assessment. LASSO analysis was performed to build a prognostic model. We constructed a model containing 8 DEBMlncRNAs (AC004034.1, AL662797.1, NR2F1-AS1, SETBP1-DT, AC011503.2, AC093010.2, LINC00649 and LINC02321). The prognostic risk model accurately predicted the prognosis of BCa patients and revealed that tumor aggressiveness and distant metastasis were associated with higher risk scores. In this model, we constructed a nomogram to assist clinical decision-making based on clinicopathological characteristics such as age, T, and N. The model also showed good predictive power for the tumor microenvironment and mutational burden. We validated the expression of eight lncRNAs using the dataset GSE133624 and two human bladder cancer cell lines (5637, BIU-87) and examined the expression and cellular localization of LINC00649 and AC011503.2 using a human bladder cancer tissue chip. We found that knockdown of LINC00649 expression in 5637 cells promoted the proliferation of 5637 cells.Our eight DEBMlncRNA risk models provide new insights into predicting prognosis, tumor invasion, and metastasis in BCa patients.

Citing Articles

Development and validation of a machine learning model to predict the risk of lymph node metastasis in early-stage supraglottic laryngeal cancer.

Wang H, He Z, Xu J, Chen T, Huang J, Chen L Front Oncol. 2025; 15:1525414.

PMID: 40018413 PMC: 11865678. DOI: 10.3389/fonc.2025.1525414.


Comprehensive analysis of basement membrane-related genes showed that NELL2 is a new therapeutic target for colorectal cancer.

Wang W, Dai Z, Ge C, Zhou X, Zhan Y, Chen C Discov Oncol. 2025; 16(1):195.

PMID: 39961875 PMC: 11832829. DOI: 10.1007/s12672-025-01979-5.


Prognosis prediction of head and neck squamous cell carcinoma through the basement membrane-related lncRNA risk model.

Bu W, Cao M, Wu X, Gao Q Front Mol Biosci. 2024; 11:1421335.

PMID: 39507635 PMC: 11538083. DOI: 10.3389/fmolb.2024.1421335.


Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma.

Zhang H, Zhang X, Huang Z, Zhang H Biol Direct. 2024; 19(1):79.

PMID: 39256753 PMC: 11389425. DOI: 10.1186/s13062-024-00529-3.


Silencing LINC00663 inhibits inflammation and angiogenesis through downregulation of NR2F1 via EBF1 in bladder cancer.

Zhong X, Sun L, Liu J, Yang X, Hou M, Wang X RNA Biol. 2024; 21(1):9-22.

PMID: 39219375 PMC: 11188801. DOI: 10.1080/15476286.2024.2368304.


References
1.
Deng Y, Zhang F, Sun Z, Wang S . Development and Validation of a Prognostic Signature Associated With Tumor Microenvironment Based on Autophagy-Related lncRNA Analysis in Hepatocellular Carcinoma. Front Med (Lausanne). 2021; 8:762570. PMC: 8712323. DOI: 10.3389/fmed.2021.762570. View

2.
Kavasi R, Neagu M, Constantin C, Munteanu A, Surcel M, Tsatsakis A . Matrix Effectors in the Pathogenesis of Keratinocyte-Derived Carcinomas. Front Med (Lausanne). 2022; 9:879500. PMC: 9100789. DOI: 10.3389/fmed.2022.879500. View

3.
de Kouchkovsky I, Zhang L, Philip E, Wright F, Kim D, Natesan D . promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021; 9(5). PMC: 8118032. DOI: 10.1136/jitc-2020-002127. View

4.
Lopez-Beltran A, Cimadamore A, Blanca A, Massari F, Vau N, Scarpelli M . Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021; 13(1). PMC: 7795541. DOI: 10.3390/cancers13010131. View

5.
Xia Q, Zhang Y, Li L, Lu J, Xun Y, Sun J . Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma. Dis Markers. 2022; 2022:8131007. PMC: 8967576. DOI: 10.1155/2022/8131007. View